Back

Thromboembolic risk in patients with atrial fibrillation and valvular heart disease according to the EHRA Type 2 definition: beyond mitral stenosis and mechanical prosthetic heart valve.

18 March 2019 (14:30 - 14:40)
Organised by:
Congress Presentation Part of: Late-breaking trials 3 Stroke in Atrial Fibrillation EHRA Premium Access EHRA 2019

About the speaker

Photo
Miss Line Melgaard

Aalborg University Hospital, Aalborg (Denmark)

10 More presentations in this session

Presentation thumbnail
Uninterrupted edoxaban versus vitamin k antagonists for ablation of atrial fibrillation:the ELIMINATE-AF Trial
Professor S. Hohnloser (Frankfurt, DE)
Slides Video
Presentation thumbnail
ELIMINATE-AF Trial - Discussion
Professor T. Potpara (Belgrade, RS)
Slides Video
Presentation thumbnail
Internal vs. external electrical cardioversion of atrial arrhythmias in patients with an implantable cardioverter-defibrillator: a randomised controlled clinical trial
Doctor J. Luker (Cologne, DE)
Slides Video
Presentation thumbnail
Internal vs. external electrical cardioversion of atrial arrhythmias in patients with an implantable cardioverter-defibrillator: a randomised controlled clinical trial - Discussion
Professor I. Van Gelder (Groningen, NL)
Slides Video
Presentation thumbnail
Thromboembolic risk in patients with atrial fibrillation and valvular heart disease according to the EHRA Type 2 definition: beyond mitral stenosis and mechanical prosthetic heart valve - Discussion
Professor P. Kirchhof (Hamburg, DE)
Slides Video

Access the full session

Session thumbnail
Late-breaking trials 3

The Event

Event poster

EHRA 2019

18 March 2019 14:30 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources